Announced Tue, 14 Jul · 20:30 IST
Zydus clarifies Delhi HC order restricting cancer drug Ikra supply - says not material
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.5%1-day move
₹1133.80
prior close
₹1145.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.6-0.8-0.6-0.7+1.5+0.9+1.3+1.1-0.8-2.1————
Up moveDown movePending
AI summary
Delhi High Court has temporarily restricted Zydus Lifesciences from supplying its cancer drug Ikra in a patent dispute with AbbVie. In response to an NSE query, the company clarified that this court order is not material under SEBI listing rules or its own materiality policy. Zydus noted no unusual movement in its share price on July 14 and believes there is no material impact on the business.
Likely market impact
Temporary supply curb on one cancer drug due to patent dispute; company downplays material impact on business or shares.